Please login to the form below

Not currently logged in
Email:
Password:

Myalept

This page shows the latest Myalept news and features for those working in and with pharma, biotech and healthcare.

R&D productivity takes off

R&D productivity takes off

For example, Amgen's Blincyto (blinatumomab) for a rare form of leukaemia has been priced at $178, 000 a year, while AZ's Myalept (metreleptin) for the ultra-rare metabolic disorder

Latest news

  • Nexium windfall lifts AZ in third quarter Nexium windfall lifts AZ in third quarter

    Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals. ... The latter will pay $325m upfront to acquire the global rights to Myalept, subject to an existing distributor

  • FDA approves AZ’s fish oil drug FDA approves AZ’s fish oil drug

    Epanova gets green light to reduce high levels of fat in the blood

  • AZ gets limited approval for metreleptin in US AZ gets limited approval for metreleptin in US

    First FDA-backed treatment for rare disease lipodystrophy. AstraZeneca's Myalept has become the first approved treatment for the rare disease lipodystrophy after getting a green light from the FDA. ... Myalept will be "a much-needed treatment option for

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics